Monday, July 25, 2016

BioLight Life Sciences focusing on ophthalmic portfolio

BioLight Life Sciences focusing on ophthalmic portfolio

December 8, 2015 by · Leave a Comment 

Tweet BioLight Life Sciences Investments (OTCQX:BLGTY; TASE:BOLT) is now defining itself as an ophthalmology company after spending several years assembling a cluster of investments in the sector as well as in cancer diagnostics. “We believe there is a huge value potential from the ophthalmic therapeutics and diagnostics we have gathered,” CEO, Suzana Nahum Zilberberg, says […]

BioLight in DES diagnostic collaboration with Ora

BioLight in DES diagnostic collaboration with Ora

June 15, 2015 by · Leave a Comment 

Tweet BioLight Life Sciences Investments (OTCQX:BLGTY; TASE:BOLT) has expanded its relationship with Ora Inc., with the signing of a collaboration agreement to advance the clinical, regulatory and commercial development of BioLight’s TeaRx multi-parameter diagnostic test for dry eye syndrome (DES). BioLight and Ora will jointly fund the clinical study and other activities required to obtain […]

Ocular Therapeutix eyeing sustained drug delivery

Ocular Therapeutix eyeing sustained drug delivery

March 17, 2015 by · Leave a Comment 

Tweet Ocular Therapeutix (NASDAQ:OCUL) is aiming to transform the treatment of eye diseases with sustained-release therapeutics, creating a paradigm shift from frequently administered topical ophthalmic drugs to an entire course of therapy in as little as a single dose. “We have multiple late-stage product candidates based on our proven hydrogel technology platform, addressing the largest […]

BioLight units post positive study results

BioLight units post positive study results

February 2, 2015 by · Leave a Comment 

Tweet BioLight Life Sciences Investments (OTC:BLGTY; TASE:BOLT) has released positive study results from two subsidiaries developing the CellDetect non-invasive test for detecting bladder cancer in urine and the TeaRx diagnostic tests for dry eye. CellDetect successfully achieved the study’s primary endpoint for effectively detecting the recurrence of bladder cancer in subjects with a history of […]

Mati Therapeutics gets another U.S. patent

Mati Therapeutics gets another U.S. patent

June 30, 2014 by · Leave a Comment 

Tweet Closely held Mati Therapeutics has received a U.S. patent covering its novel punctal plug delivery system for treatment of ocular indications (PPDS), including certain features for retaining the punctal plug within the nasolacrimal system of the eye during drug elution. The patent is titled, “Nasolacrimal Drainage System Implants For Drug Therapy.” Mati is actively […]

Mati Therapeutics isn’t your traditional biotech startup

Mati Therapeutics isn’t your traditional biotech startup

June 10, 2014 by · Leave a Comment 

Tweet Not quite two years old yet, closely held Mati Therapeutics is conducting a pre-Phase 3 clinical trial with an ocular punctal plug delivery system (PPDS) that could become a preferred alternative to eye drops. “Because of the Phase 2 trials conducted by QLT on this technology, we have a different risk-reward profile than a […]

Roth starts Can-Fite BioPharma at buy

Roth starts Can-Fite BioPharma at buy

October 1, 2013 by · Leave a Comment 

Tweet Roth Capital Partners has initiated coverage of Can-Fite BioPharma (OTCQB:CANFY; TASE:CFBI) with a “buy” rating and $15 price target, suggesting investors own the stock ahead of two data readouts in the fourth quarter this year. Can-Fite is an Israeli company, whose ADRs recently started trading in the U.S. They closed at $5.03 on Monday. […]

Circadian to expand product development portfolio

Circadian to expand product development portfolio

October 2, 2012 by · Leave a Comment 

Tweet Australia’s Circadian Technologies (ASX:CIR), which has been advancing its lead drug candidate, VGX-100, as a treatment for cancer and eye diseases, is considering a move to expand its pipeline by developing another drug candidate in its portfolio, VGX-300, in specific eye disease indications. “In this way, the market can look at us as a […]

Email Newsletters with Constant Contact
Google+